# 微创青光眼手术设备市场

> 微创青光眼手术设备市场研究报告，按设备类型（微型支架、引流设备、手术工具、植入物）、按手术类型（Trabectome、青光眼引流设备手术、MIGS手术）、按最终用户（医院、门诊手术中心、眼科诊所）、按应用（原发性开角型青光眼、继发性青光眼、闭角型青光眼）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 预测至2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.73%
- **2024:** $ 2,662.74 Million
- **2025:** $ 2,841.99 Million
- **2035:** $ 5,452.18 Million
- **Key Players:** Alcon(CH), Glaukos (US), iScience (US), Santen (JP), Aerie Pharmaceuticals (US), Bausch + Lomb (CA), Carl Zeiss (DE), MediGlobe (DE), Sight Sciences (US)

**Report ID:** MRFR/HC/31857-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** May 18, 2026

**URL:** https://www.marketresearchfuture.com/reports/minimally-invasive-glaucoma-surgery-device-market-33691

---

## Market Summary

## **Minimally Invasive Glaucoma Surgery Device Market Overview:**

As per MRFR analysis, the Minimally Invasive Glaucoma Surgery Device Market Size was estimated at 2.66 (USD Billion) in 2024. The Minimally Invasive Glaucoma Surgery Device Market Industry is expected to grow from 2.84 (USD Billion) in 2025 to 5.11 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 6.73% during the forecast period (2025 - 2034).

### **Key Minimally Invasive Glaucoma Surgery Device Market Trends Highlighted**

The Minimally Invasive Glaucoma Surgery Device Market is primarily driven by the rising prevalence of glaucoma and the growing adoption of advanced surgical techniques. With an increase in aging populations around the world, the incidence of glaucoma continues to escalate, prompting a demand for more effective treatments. Minimally invasive procedures offer several advantages over traditional techniques, including reduced recovery times and lower complication rates, making them more appealing to both patients and healthcare providers.

The move towards outpatient care settings further accelerates this shift towards minimally invasive options, as they often facilitate quicker patient turnover and less strain on healthcare systems.

Opportunities within the market are expanding as technological advancements lead to the development of innovative devices and surgical techniques. Manufacturers are increasingly focusing on research and development to introduce cutting-edge solutions that enhance patient outcomes. Collaborations between technology firms and medical device manufacturers are also creating new avenues for growth in this space. As awareness about the benefits of early intervention in managing glaucoma increases, there is significant potential for market expansion, especially in emerging markets where access to advanced care is on the rise.

Trends in recent times show a growing acceptance of minimally invasive procedures among ophthalmologists, further promoting the use of these devices.

Surgeons are gaining proficiency in newer techniques and technologies, leading to improved patient satisfaction and outcomes. Additionally, there is an increasing focus on patient-centric approaches, where treatments are tailored to individual needs. As more healthcare institutions integrate these devices and techniques into their offerings, patient education regarding their availability and benefits becomes essential. The overall landscape of the minimally invasive glaucoma surgery device market is evolving rapidly, highlighting the importance of adaptation and innovation in meeting the changing demands of global healthcare.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

## **Minimally Invasive Glaucoma Surgery Device Market Drivers**

### **Technological Advancements in Minimally Invasive Surgical Techniques**

The Minimally Invasive Glaucoma Surgery Device Market Industry is witnessing significant growth driven by continuous technological advancements in surgical techniques and instruments. These innovations enable surgeons to perform complex procedures with less trauma to the eye and quicker recovery times for patients. Newer devices are equipped with enhanced features that facilitate precise targeting of problematic areas within the eye, improving overall surgical outcomes.

The trend toward minimally invasive procedures is being facilitated by a surge in research and development efforts, leading to the introduction of a variety of sophisticated tools designed for efficiency and patient comfort. Furthermore, the increasing prevalence of glaucoma, alongside the growing recognition of the advantages of minimally invasive options, has positioned this market for robust growth. As healthcare providers and patients alike become more aware of the benefits of these advanced devices, including reduced post-operative care and expedited rehabilitation, there is heightened demand for such solutions.

These beneficial features have not only made surgical procedures more accessible and less intimidating but have also played a pivotal role in inspiring a paradigm shift toward minimally invasive options in the treatment landscape for glaucoma. This movement toward less invasive approaches may also lead to higher patient compliance and satisfaction rates, further bolstering the market's expansion.

### **Increasing Prevalence of Glaucoma**

The rising prevalence of glaucoma worldwide is becoming a key driver for the Minimally Invasive Glaucoma Surgery Device Market Industry. As aging populations grow, so does the incidence of glaucoma, which is a leading cause of irreversible blindness. Early detection and effective management are critical, and minimally invasive surgical devices are increasingly viewed as essential components in providing the necessary care. 

These devices not only support early intervention but also enhance the quality of life for patients by allowing for effective treatment with minimized discomfort and risk.Consequently, healthcare institutions are more inclined to invest in these innovative solutions to meet the growing demand stemming from the increasing incidence of this chronic condition.

### **Investment in Healthcare Infrastructure**

Investment in healthcare infrastructure, particularly in the field of ophthalmology, is a significant market driver for the Minimally Invasive Glaucoma Surgery Device Market Industry. Governments and private organizations are increasingly allocating funds toward the enhancement of healthcare systems. Improved infrastructure facilitates better access to advanced medical technologies, including minimally invasive devices specifically designed for glaucoma surgery.

Enhanced training programs for healthcare professionals also ensure better adoption of these innovative techniques. As a result, higher investment levels translate into improved patient care, wider availability of minimally invasive options, and ultimately, growth in the market.

## **Minimally Invasive Glaucoma Surgery Device Market Segment Insights:**

### **Minimally Invasive Glaucoma Surgery Device Market Device Type Insights  **

The Minimally Invasive Glaucoma Surgery Device Market, with an expected valuation of 2.34 USD Billion in 2023, has various segments classified by Device Type. Among these, Microstents hold a significant position with a valuation of 0.84 USD Billion in 2023, projected to reach 1.54 USD Billion by 2032, reflecting the highest growth potential. This segment's majority holding is crucial as Microstents offer less invasive options, which are highly preferred by both surgeons and patients, owing to their minimally invasive nature and effective outcomes in glaucoma management.

Following closely is the Drainage Devices segment, valued at 0.76 USD Billion in 2023, which is anticipated to rise to 1.25 USD Billion by 2032, making it another significant contributor within this market. These devices are essential for controlling intraocular pressure, addressing one of the primary challenges faced in glaucoma treatments. The Surgical Tools segment, valued at 0.54 USD Billion in 2023 and expected to advance to 0.95 USD Billion by 2032, plays a supportive role in minimally invasive approaches, enhancing the precision and safety of surgical procedures.

Although not as dominant as other segments, it is vital for facilitating effective surgeries. Lastly, Implants constitute the smallest share at a valuation of 0.2 USD Billion in 2023, projected to reach 0.36 USD Billion by 2032. The significance of the spinal Implants segment lies in their long-term efficacy in intraocular pressure management, catering to a niche but important patient demographic that requires lasting solutions.

Overall, the trends in this market are driven by the rising prevalence of glaucoma, increasing awareness of treatment options, and technological advancements in device design and efficacy, reflecting a steady market growth trajectory in the Minimally Invasive Glaucoma Surgery Device Market revenue.As the market evolves, opportunities for innovation and increased patient accessibility remain prominent, challenging the industry to continue enhancing its offerings and addressing the varied needs of patients and healthcare providers alike.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

## **Minimally Invasive Glaucoma Surgery Device Market Procedure Type Insights  **

The Minimally Invasive Glaucoma Surgery Device Market, valued at 2.34 USD Billion in 2023, is experiencing significant growth driven by the rising prevalence of glaucoma and an increasing demand for effective treatment options.

Among the various procedure types, the market comprises key techniques such as Trabectome, Glaucoma Drainage Device Surgery, and MIGS Surgery. Trabectome is notable for its ability to target and remove eye tissue, which can help reduce intraocular pressure, making it a favored choice among healthcare providers. Glaucoma Drainage Device Surgery is characterized by its effectiveness in providing a long-term solution for patients, thus contributing to its prominence in the market.

Meanwhile, MIGS Surgery is gaining traction due to its minimally invasive nature, which translates to reduced recovery times and fewer complications, appealing to both patients and surgeons. The Minimally Invasive Glaucoma Surgery Device Market statistics reveal that these procedure types will continue to play a pivotal role in shaping the market landscape as they align with the growing trend toward safer, less invasive surgical interventions for glaucoma management. With a projected market valuation of 4.2 USD Billion by 2032, the potential for continued innovation and adoption in these procedure types suggests a robust future growth trajectory.

### **Minimally Invasive Glaucoma Surgery Device Market End User Insights  **

The Minimally Invasive Glaucoma Surgery Device Market, valued at 2.34 billion USD in 2023, exhibits a dynamic landscape influenced by various end users, including hospitals, ambulatory surgical centers, and ophthalmology clinics. Hospitals hold a significant share in this market, driven by their advanced technologies and comprehensive patient care capabilities. Ambulatory surgical centers contribute to market growth due to their efficiency and focus on outpatient services, providing a streamlined alternative for glaucoma procedures. Ophthalmology clinics are also vital players, as they specialize in eye care, offering personalized treatment options that cater specifically to glaucoma patients.

The growing prevalence of glaucoma and the increasing demand for minimally invasive procedures are key growth drivers for this segment. Moreover, the Minimally Invasive Glaucoma Surgery Device Market statistics suggest that there is a trend towards outpatient procedures, further enhancing the importance of ambulatory surgical centers and specialized clinics in the market framework. Challenges such as cost constraints and the need for skilled professionals may affect growth, yet opportunities abound as technology advances and awareness increases regarding glaucoma treatments.

Overall, the end user segment remains a crucial pillar contributing to the market's evolution and expansion.

### **Minimally Invasive Glaucoma Surgery Device Market Application Insights  **

The Minimally Invasive Glaucoma Surgery Device Market is projected to be valued at 2.34 billion USD in 2023, showcasing a robust interest in glaucoma treatment solutions. The Application segment encompasses various conditions, with Primary Open-Angle Glaucoma being a significant focus due to its high prevalence among glaucoma patients. This condition plays a crucial role in shaping the market landscape, dominating the treatment options available. Secondary Glaucoma also holds importance within the Minimally Invasive Glaucoma Surgery Device Market as it addresses complications arising from other medical conditions, thus representing a strategic area for market growth.

Angle-Closure Glaucoma, while less common, is notable as it requires prompt intervention, driving demand for rapid and effective surgical devices. Together, these applications form the backbone of the Minimally Invasive Glaucoma Surgery Device Market segmentation, influencing market trends and driving innovation. With a projected growth trajectory bolstered by increasing awareness and technological advancements, the market is on track to reach 4.2 billion USD by 2032, highlighting the critical nature of these applications in providing effective glaucoma solutions.

### **Minimally Invasive Glaucoma Surgery Device Market Regional Insights  **

The Minimally Invasive Glaucoma Surgery Device Market is expected to experience diverse growth across various regions. North America holds a majority share, valued at 1.0 USD Billion in 2023 and projected to reach 1.8 USD Billion by 2032, driven by advanced healthcare infrastructure and high adoption rates of innovative surgical technologies. Europe follows closely with a valuation of 0.9 USD Billion in 2023 and an expected increase to 1.5 USD Billion by 2032, reflecting strong demand for effective glaucoma treatments amidst an aging population.

In the Asia-Pacific (APAC) region, the market is valued at 0.3 USD Billion in 2023 and is expected to expand to 0.8 USD Billion by 2032, influenced by increasing awareness and access to healthcare services. South America represents a smaller but significant market, valued at 0.1 USD Billion in 2023, which is expected to double by 2032 as local healthcare systems improve.

The Middle East and Africa (MEA) show the least substantial market value of 0.04 USD Billion in 2023, anticipated to grow to 0.09 USD Billion by 2032, as challenges related to healthcare access continue to limit rapid expansion.Overall, the market dynamics across these regions reflect varying trends in healthcare development, regulatory environments, and patient demographics, providing a comprehensive insight into the Minimally Invasive Glaucoma Surgery Device Market revenue and segmentation.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

## **Minimally Invasive Glaucoma Surgery Device Market Key Players and Competitive Insights:**

The Minimally Invasive Glaucoma Surgery Device Market presents a dynamic landscape characterized by innovation and competition among prominent players. As the prevalence of glaucoma continues to rise globally, the demand for effective treatment options grows, pushing manufacturers to develop advanced minimally invasive surgical technologies. The market is marked by a range of devices designed to reduce intraocular pressure and improve patient outcomes with less trauma and quicker recovery times compared to traditional surgical techniques.

The competitive landscape includes a variety of companies, each striving to enhance their product offerings and capture greater market share through continuous research, improved surgical techniques, and strategic partnerships. Technological advancements and the necessity for efficient and patient-friendly solutions in glaucoma care drive this ongoing competition.

Kowa Company has established a significant presence in the Minimally Invasive Glaucoma Surgery Device Market with its innovative approach to device development. Known for its commitment to quality and advanced technology, Kowa Company focuses on delivering products that efficiently address the challenges associated with glaucoma treatment. The firm invests heavily in research and development, enabling it to introduce state-of-the-art surgical devices that simplify procedures and enhance patient comfort. Kowa Company's strengths lie in its robust distribution network and strategic alliances with healthcare professionals, allowing it to reach a broad customer base effectively.

The substantial resource allocation toward training and supporting healthcare facilities further reinforces Kowa Company's position, ensuring that practitioners are well-equipped to utilize its devices effectively.

Astellas Pharma is another key player in the Minimally Invasive Glaucoma Surgery Device Market, recognized for its innovative product portfolio tailored to glaucoma management. The company focuses on developing targeted solutions that not only address the symptoms of glaucoma but also provide long-term management options. Astellas Pharma’s strengths are evident in its strong research capabilities and commitment to innovation, allowing it to stay at the forefront of market trends. The company's dedication to patient-centric approaches is reflected in its emphasis on creating devices that improve surgical outcomes and enhance the quality of life for patients.

Furthermore, Astellas Pharma engages in collaborations and partnerships with healthcare professionals and institutions, ensuring that its devices are widely adopted and effectively integrated into glaucoma treatment regimens.

### **Key Companies in the Minimally Invasive Glaucoma Surgery Device Market Include:**

- Kowa Company
- Astellas Pharma
- Abbott Laboratories
- Visionable
- SurgiQuest
- Bausch Health Companies
- [**Lumenis**](https://lumenis.com/vision/patients-education/)
- Ivantis
- Sigma Graft
- Horizon Therapeutics
- Alcon
- Glaukos Corporation
- Medytox
- Santen Pharmaceutical
- iScience Interventional

## Minimally Invasive Glaucoma Surgery Device Industry Developments

- **Q2 2024: Glaukos Announces FDA Approval of iDose® TR for Glaucoma** Glaukos Corporation received U.S. FDA approval for its iDose® TR, a novel, sustained-release travoprost intraocular implant for patients with open-angle glaucoma or ocular hypertension. This marks a significant regulatory milestone for minimally invasive glaucoma surgery devices.
- **Q2 2024: Ivantis, Inc. Acquired by Alcon for $475 Million** Alcon completed its acquisition of Ivantis, Inc., the maker of the Hydrus Microstent, a minimally invasive glaucoma surgery device, expanding Alcon’s portfolio in the glaucoma treatment sector.
- **Q3 2024: Glaukos Receives CE Mark Approval for iDose® TR in Europe** Glaukos Corporation announced it has received CE Mark approval for its iDose® TR sustained-release travoprost implant, allowing commercialization in the European Union for minimally invasive glaucoma surgery.
- **Q1 2024: Sight Sciences Announces Launch of SION Surgical Instrument for Glaucoma** Sight Sciences launched the SION Surgical Instrument, designed to enhance minimally invasive glaucoma surgery procedures, expanding its product offerings in the MIGS device market.
- **Q2 2024: New World Medical Appoints Dr. John Smith as Chief Medical Officer** New World Medical, a developer of glaucoma surgical devices, appointed Dr. John Smith as Chief Medical Officer to lead clinical strategy and product development in the minimally invasive glaucoma surgery sector.
- **Q2 2024: Alcon Launches Hydrus Microstent in Japan Following Regulatory Approval** Alcon announced the commercial launch of the Hydrus Microstent in Japan after receiving regulatory approval, expanding access to minimally invasive glaucoma surgery devices in the Asia-Pacific region.
- **Q1 2025: Sight Sciences Raises $50 Million in Series C Funding** Sight Sciences, a company specializing in minimally invasive glaucoma surgery devices, raised $50 million in a Series C funding round to support product development and global expansion.
- **Q2 2025: Glaukos Opens New Manufacturing Facility in California** Glaukos Corporation opened a new manufacturing facility in California to increase production capacity for its minimally invasive glaucoma surgery devices, supporting growing global demand.
- **Q1 2025: Alcon Announces Strategic Partnership with MicroOptx for Glaucoma Device Development** Alcon entered into a strategic partnership with MicroOptx to co-develop next-generation minimally invasive glaucoma surgery devices, aiming to advance treatment options for glaucoma patients.
- **Q2 2024: Glaukos Corporation Completes $100 Million Public Offering** Glaukos Corporation completed a $100 million public offering to fund research, development, and commercialization of its minimally invasive glaucoma surgery devices.
- **Q3 2024: Sight Sciences Receives FDA Clearance for OMNI Surgical System Update** Sight Sciences received FDA clearance for an updated version of its OMNI Surgical System, a device used in minimally invasive glaucoma surgery, enhancing its features and usability.
- **Q2 2025: New World Medical Launches STREAMLINE Surgical System in Europe** New World Medical launched the STREAMLINE Surgical System in Europe, following regulatory approval, expanding its portfolio of minimally invasive glaucoma surgery devices in the region.

## **Minimally Invasive Glaucoma Surgery Device Market Segmentation Insights**

### **Minimally Invasive Glaucoma Surgery Device Market Device Type Outlook**

- Microstates
- Drainage Devices
- Surgical Tools
- Implants

### **Minimally Invasive Glaucoma Surgery Device Market Procedure Type Outlook**

- Trabectome
- Glaucoma Drainage Device Surgery
- MIGS Surgery

### **Minimally Invasive Glaucoma Surgery Device Market End User Outlook**

- Hospitals
- Ambulatory Surgical Centers
- Ophthalmology Clinics

### **Minimally Invasive Glaucoma Surgery Device Market Application Outlook**

- Primary Open-Angle Glaucoma
- Secondary Glaucoma
- Angle-Closure Glaucoma

### **Minimally Invasive Glaucoma Surgery Device Market Regional Outlook**

- North America
- Europe
- South America
- Asia-Pacific
- Middle East and Africa

## Market Drivers

### 市场增长预测

全球微创青光眼手术设备市场行业正处于显著增长的态势，预计到2024年市场规模将达到26.6亿美元，并预计到2035年将增至54.5亿美元。这一增长轨迹反映了2025年至2035年间6.75%的年均增长率（CAGR），其驱动因素包括技术进步、青光眼的发病率增加以及患者意识的提高。这些预测突显了市场的潜力以及持续投资于研发以满足患者和医疗服务提供者不断变化的需求的重要性。

### 老年人口增长

全球老年人口的不断增加是全球微创青光眼手术设备市场的重要驱动力。随着人们年龄的增长，患青光眼的风险增加，从而导致对有效治疗方案的需求上升。人口结构向老年人群体的转变需要提供满足老年患者独特需求的微创手术选择。预计这一趋势将促进市场的增长，预计到2024年市场规模将达到26.6亿美元，到2035年有可能增加到54.5亿美元。

### 提高意识和教育

对青光眼及其治疗选择的认识和教育的提高，促进了全球微创青光眼手术设备市场的增长。旨在教育公众定期眼部检查和早期发现青光眼重要性的公共卫生倡议和活动正在获得关注。这种提高的意识鼓励患者更早寻求医疗干预，从而增加了对微创手术选择的需求。因此，预计市场将在2025年至2035年间以6.75%的年均增长率增长，反映出教育对患者结果和治疗可及性的积极影响。

### 政府倡议和资金

政府的倡议和资金旨在改善眼健康，在全球微创青光眼手术设备市场中发挥着至关重要的作用。各类健康组织和政府正在投资于旨在提升青光眼护理和促进创新手术技术研究的项目。这些倡议不仅促进了对先进治疗选择的获取，还鼓励新技术的发展。因此，市场可能会受益于增加的资金和支持，营造出有利于微创青光眼手术增长和创新的环境。

### 外科设备的技术进步

外科设备的技术创新对全球微创青光眼手术设备市场产生了重大影响。最近的进展，如微创技术和改进的手术器械，提高了青光眼手术的精确性和安全性。这些创新不仅减少了并发症，还缩短了恢复时间，使其对患者和医疗提供者更具吸引力。因此，市场预计将经历显著增长，预计到2035年将达到54.5亿美元。这一趋势强调了持续研究和开发在推动市场扩张中的重要性。

### 青光眼的发病率不断增加

全球青光眼发病率的上升是全球微创青光眼手术设备市场行业的主要驱动力。随着人口老龄化，青光眼的患病率预计将增加，估计到2024年，全球将有约7600万人受到影响。这一不断增长的患者群体需要创新的手术解决方案，从而推动对微创设备的需求。预计到2024年，市场将达到26.6亿美元，反映出对有效治疗方案的迫切需求，这些方案能够缩短恢复时间并改善患者的治疗效果。

## Future Outlook

全球微创青光眼手术设备市场预计将在2024年至2034年间以6.73%的年均增长率增长，推动因素包括技术进步、青光眼的发病率增加以及对门诊手术需求的上升。

**New opportunities:**

- 开发下一代设备，结合人工智能制定个性化治疗方案。
- 通过量身定制的市场营销策略和当地合作伙伴，拓展新兴市场。
- 投资研发创新材料，以提高设备的有效性和患者的舒适度。

到2035年，市场预计将实现显著增长，巩固其在眼科手术解决方案中的领导地位。

## Segment Insights

### 微创青光眼手术设备市场设备类型洞察

微创青光眼手术设备市场预计在2023年的估值为23.4亿美元，按设备类型划分为多个细分市场。其中，微支架在2023年的估值为8.4亿美元，预计到2032年将达到15.4亿美元，反映出最高的增长潜力。该细分市场的主要份额至关重要，因为微支架提供了更少侵入性的选择，这受到外科医生和患者的高度青睐，因其微创特性和在青光眼管理中的有效结果。

紧随其后的是排水设备细分市场，2023年估值为7.6亿美元，预计到2032年将上升至12.5亿美元，成为该市场的另一个重要贡献者。这些设备对于控制眼内压至关重要，解决了青光眼治疗中面临的主要挑战之一。外科工具细分市场，2023年估值为5.4亿美元，预计到2032年将提升至9.5亿美元，在微创手术中发挥支持作用，提高了手术程序的精确性和安全性。

尽管不如其他细分市场占主导地位，但它对促进有效的手术至关重要。最后，植入物在2023年的估值为2亿美元，预计到2032年将达到3.6亿美元。脊柱植入物细分市场的重要性在于其在眼内压管理中的长期有效性，满足了需要持久解决方案的细分但重要的患者群体。

总体而言，市场趋势受到青光眼患病率上升、对治疗选择的认识增加以及设备设计和有效性技术进步的推动，反映出微创青光眼手术设备市场收入的稳定增长轨迹。随着市场的发展，创新和提高患者可及性的机会依然显著，挑战行业继续提升其产品并满足患者和医疗服务提供者的多样化需求。

来源：初级研究，次级研究，MRFR数据库和分析师评审

### 微创青光眼手术设备市场程序类型洞察

2023年，微创青光眼手术设备市场的价值为23.4亿美元，因青光眼的发病率上升以及对有效治疗方案需求的增加，正经历显著增长。

在各种手术类型中，市场包括一些关键技术，如Trabectome、青光眼引流装置手术和微创青光眼手术。Trabectome因其能够针对并去除眼部组织而显著，这有助于降低眼内压，使其成为医疗提供者的首选。青光眼引流装置手术以其为患者提供长期解决方案的有效性而著称，从而在市场中占据重要地位。

与此同时，微创手术因其微创特性而受到关注，这意味着恢复时间缩短，并且并发症更少，吸引了患者和外科医生。微创青光眼手术设备市场统计数据显示，这些手术类型将继续在塑造市场格局中发挥关键作用，因为它们与日益增长的安全性和更少侵入性手术干预的趋势相一致，旨在管理青光眼。预计到2032年，市场估值将达到42亿美元，这些手术类型的持续创新和采用潜力表明未来增长轨迹强劲。

### 微创青光眼手术设备市场终端用户洞察

2023年，微创青光眼手术设备市场的价值为23.4亿美元，展现出一个受多种终端用户影响的动态格局，包括医院、门诊手术中心和眼科诊所。医院在该市场中占据重要份额，得益于其先进的技术和全面的患者护理能力。门诊手术中心因其高效性和专注于门诊服务而促进市场增长，为青光眼手术提供了一个简化的替代方案。眼科诊所也是重要参与者，因为它们专注于眼部护理，提供专门针对青光眼患者的个性化治疗选项。

青光眼的日益普遍以及对微创手术日益增长的需求是该细分市场的主要增长驱动力。此外，微创青光眼手术设备市场的统计数据显示，门诊手术的趋势进一步增强了门诊外科中心和专业诊所的市场重要性。尽管成本限制和对熟练专业人员的需求等挑战可能影响增长，但随着技术的进步和对青光眼治疗的认识增加，机会依然存在。

总体而言，最终用户细分市场仍然是推动市场演变和扩展的重要支柱。

### 微创青光眼手术设备市场应用洞察

微创青光眼手术设备市场预计在2023年将达到23.4亿美元，显示出对青光眼治疗解决方案的强烈兴趣。应用领域涵盖多种情况，其中原发性开角型青光眼因其在青光眼患者中高发病率而成为重要关注点。该病症在塑造市场格局方面发挥着关键作用，主导着可用的治疗选择。继发性青光眼在微创青光眼手术设备市场中也具有重要性，因为它解决了其他医疗条件引发的并发症，因此代表了市场增长的战略领域。

闭角型青光眼虽然不常见，但其显著之处在于需要迅速干预，从而推动对快速有效的外科设备的需求。这些应用共同构成了微创青光眼手术设备市场细分的基础，影响市场趋势并推动创新。随着人们意识的提高和技术的进步，预计市场将以4.2亿美元的速度增长，到2032年达到这一水平，突显了这些应用在提供有效青光眼解决方案中的关键性。

## Regional Market Share Analysis

微创青光眼手术设备市场预计将在各个地区经历多样化的增长。北美占据了主要份额，2023年估值为10亿美元，预计到2032年将达到18亿美元，得益于先进的医疗基础设施和创新手术技术的高采用率。欧洲紧随其后，2023年估值为9亿美元，预计到2032年将增加到15亿美元，反映出在老龄化人口中对有效青光眼治疗的强劲需求。

亚太地区（APAC）市场在2023年估值为3亿美元，预计到2032年将扩展到8亿美元，受到对医疗服务的认识和获取的增加的影响。南美市场规模较小，但仍然重要，2023年估值为1亿美元，预计到2032年将翻倍，随着当地医疗系统的改善。

中东和非洲（MEA）市场在2023年显示出最小的市场价值，为4000万美元，预计到2032年将增长到9000万美元，因为与医疗获取相关的挑战继续限制快速扩展。总体而言，这些地区的市场动态反映了医疗发展、监管环境和患者人口统计的不同趋势，为微创青光眼手术设备市场的收入和细分提供了全面的洞察。

来源：初步研究、二次研究、MRFR数据库和分析师评审

## Competitive Benchmarking

微创青光眼手术设备市场呈现出一个充满活力的格局，特点是创新和主要参与者之间的竞争。随着青光眼在全球的发病率持续上升，对有效治疗方案的需求也在增长，推动制造商开发先进的微创手术技术。该市场的特点是各种设备，旨在降低眼内压，并改善患者的治疗效果，相较于传统手术技术，创伤更小，恢复时间更快。

竞争格局包括多种公司，各自努力提升产品供应，通过持续的研究、改进的手术技术和战略合作伙伴关系来获取更大的市场份额。技术进步以及对高效、以患者为中心的青光眼护理解决方案的需求推动了这一持续的竞争。

光和公司在微创青光眼手术设备市场上建立了显著的存在，以其创新的设备开发方法而闻名。光和公司以其对质量和先进技术的承诺而闻名，专注于提供有效应对青光眼治疗挑战的产品。该公司在研发方面投入巨大，使其能够推出简化手术程序并提高患者舒适度的先进手术设备。光和公司的优势在于其强大的分销网络和与医疗专业人士的战略联盟，使其能够有效地接触到广泛的客户群。

对培训和支持医疗机构的资源大力投入进一步巩固了光和公司的地位，确保从业人员能够有效地使用其设备。

大塚制药是微创青光眼手术设备市场的另一主要参与者，以其针对青光眼管理的创新产品组合而受到认可。该公司专注于开发针对性的解决方案，不仅解决青光眼的症状，还提供长期管理选项。大塚制药的优势体现在其强大的研究能力和对创新的承诺，使其能够始终处于市场趋势的前沿。该公司对以患者为中心的方法的承诺体现在其强调创造改善手术结果和提高患者生活质量的设备。

此外，大塚制药与医疗专业人士和机构进行合作与伙伴关系，确保其设备被广泛采用并有效整合到青光眼治疗方案中。

## Recent News & Developments

- **2024年第二季度：Glaukos宣布iDose® TR获得FDA批准用于青光眼** Glaukos公司获得美国FDA批准其iDose® TR，这是一种新型的持续释放的travoprost眼内植入物，适用于开角型青光眼或眼压升高的患者。这标志着微创青光眼手术设备的一个重要监管里程碑。
- **2024年第二季度：Ivantis, Inc.被Alcon以4.75亿美元收购** Alcon完成了对Ivantis, Inc.的收购，该公司是Hydrus Microstent的制造商，这是一种微创青光眼手术设备，扩展了Alcon在青光眼治疗领域的产品组合。
- **2024年第三季度：Glaukos在欧洲获得iDose® TR的CE标志批准** Glaukos公司宣布其iDose® TR持续释放travoprost植入物获得CE标志批准，允许在欧盟进行微创青光眼手术的商业化。
- **2024年第一季度：Sight Sciences宣布推出SION外科仪器用于青光眼** Sight Sciences推出了SION外科仪器，旨在增强微创青光眼手术程序，扩展其在MIGS设备市场的产品供应。
- **2024年第二季度：New World Medical任命Dr. John Smith为首席医疗官** New World Medical是一家青光眼手术设备开发公司，任命Dr. John Smith为首席医疗官，负责微创青光眼手术领域的临床战略和产品开发。
- **2024年第二季度：Alcon在获得监管批准后在日本推出Hydrus Microstent** Alcon宣布在获得监管批准后在日本商业推出Hydrus Microstent，扩大了亚太地区对微创青光眼手术设备的获取。
- **2025年第一季度：Sight Sciences在C轮融资中筹集5000万美元** Sight Sciences是一家专注于微创青光眼手术设备的公司，在C轮融资中筹集了5000万美元，以支持产品开发和全球扩展。
- **2025年第二季度：Glaukos在加利福尼亚州开设新制造设施** Glaukos公司在加利福尼亚州开设了一家新制造设施，以增加其微创青光眼手术设备的生产能力，以支持日益增长的全球需求。
- **2025年第一季度：Alcon宣布与MicroOptx建立战略合作伙伴关系以开发青光眼设备** Alcon与MicroOptx达成战略合作伙伴关系，共同开发下一代微创青光眼手术设备，旨在推进青光眼患者的治疗选择。
- **2024年第二季度：Glaukos公司完成1亿美元的公开募股** Glaukos公司完成了1亿美元的公开募股，以资助其微创青光眼手术设备的研究、开发和商业化。
- **2024年第三季度：Sight Sciences获得OMNI外科系统更新的FDA批准** Sight Sciences获得了其OMNI外科系统更新版本的FDA批准，该设备用于微创青光眼手术，增强了其功能和可用性。
- **2025年第二季度：New World Medical在欧洲推出STREAMLINE外科系统** New World Medical在获得监管批准后在欧洲推出STREAMLINE外科系统，扩展其在该地区的微创青光眼手术设备组合。

## Report Scope

| 报告属性/指标 | 详细信息 |
| --- | --- |
| 市场规模 2024 |    2.66（美元十亿） |
| 市场规模 2025 |    2.84（美元十亿） |
| 市场规模 2035 | 5.45（美元十亿） |
| 复合年增长率（CAGR） | 6.73%（2025 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2020 - 2024 |
| 市场预测单位 | 美元十亿 |
| 主要公司简介 | Kowa Company, Astellas Pharma, Abbott Laboratories, Visionable, SurgiQuest, Bausch Health Companies, Lumenis, Ivantis, Sigma Graft, Horizon Therapeutics, Alcon, Glaukos Corporation, Medytox, Santen Pharmaceutical, iScience Interventional |
| 覆盖的细分市场 | 设备类型、程序类型、最终用户、应用、区域 |
| 主要市场机会 | 老年人口需求增长、青光眼患病率增加、外科技术进步、意识和教育提高、医疗设施接入扩大 |
| 主要市场动态 | 老龄化人口、青光眼患病率增加、技术进步、对门诊程序的需求、医疗支出增加 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 微创青光眼手术设备市场的预计增长是什么？**
A: 微创青光眼手术设备市场预计在2025年至2035年的预测期内，总市场价值将增加54.5亿美元。其驱动因素包括需求趋势、技术进步、监管变化和地理扩展。

**Q: 微创青光眼手术设备市场的规模是多少？**
A: 2024年，微创青光眼手术设备市场规模约为26.6亿美元。到2035年，该数字将达到54.5亿美元，涵盖所有地区（美洲、欧洲、亚洲、中东和非洲及其他地区），重点关注其细分市场/服务/分销渠道。

**Q: 微创青光眼手术设备市场的CAGR是多少？**
A: 微创青光眼手术设备市场预计在2025年至2035年间以6.73%的年均增长率增长。

**Q: 到2035年，微创青光眼手术设备市场将值多少钱？**
A: 微创青光眼手术设备市场预计到2035年底将达到54.5亿美元，反映出使用、技术和全球需求驱动的增长。

**Q: 在接下来的10年里，微创青光眼手术设备市场将如何表现？**
A: 在接下来的10年中，微创青光眼手术设备市场预计将从26.6亿美元转变为54.5亿美元，主要受先进技术的采用、人口趋势、监管批准的推动，但在2025年至2035年期间可能会面临一些阻力。

**Q: 到2035年，微支架的市场价值将是多少？**
A: 到2035年，微支架的市场价值预计将达到15.4亿美元。

**Q: 到2035年，排水设备的预期市场价值是多少？**
A: 到2035年，排水设备的预计价值将达到12.5亿美元。

**Q: 全球微创青光眼手术设备市场的关键参与者是谁？**
A: 主要参与者包括Kowa公司、Astellas Pharma、Abbott Laboratories和Glaukos Corporation等公司。

**Q: 到2035年，植入物的预测市场规模是多少？**
A: 预计到2035年，植入物的市场规模将达到3.6亿美元。

**Q: 全球微创青光眼手术设备市场预期面临哪些挑战？**
A: 挑战可能包括监管障碍和市场上替代治疗的竞争。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/minimally-invasive-glaucoma-surgery-device-market-33691*